Genmab AS

Genmab AS EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Genmab AS (GMAB) as of Nov 22, 2026 is -81.34 %. In the previous year, Year-over-Year EBITDA Growth was 25.97 % — a change of -413.16% (lower).

EBITDA Growth YoY

-81.34 %

YoY

-413.16%

Last updated:

Year-over-Year EBITDA Growth of Genmab AS is 2025 -81.34 % . Year-over-Year EBITDA Growth of Genmab AS was 2024 25.97 % . It decreases by -413.16% lower compared to the previous year.

The Genmab AS EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
2.69 USD
Jan 1, 2019
91.12 USD
Jan 1, 2020
139.31 USD
Jan 1, 2021
-53.22 USD
Jan 1, 2022
112.22 USD
Jan 1, 2023
-15.09 USD
Jan 1, 2024
25.97 USD
Jan 1, 2025
-81.34 USD
The Genmab AS EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-81.34 %-413.16%
25.97 %-272.06%
-15.09 %-113.45%
112.22 %-310.86%
-53.22 %-138.21%
139.31 %+52.89%
91.12 %+3,291.70%
2.69 %-90.29%
27.67 %-37.32%
44.15 %-74.83%
175.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Year-over-Year EBITDA Growth of Genmab AS is -81.34 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Genmab AS since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Genmab AS

All Key Metrics — Genmab AS